ArticleJournal of cellular and molecular medicine2018

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.

Bryan Oronsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.